The FDA faces a significant morale crisis amid a recent wave of layoffs and ongoing political pressures, leading to an exodus of experienced staff across drug, device, biologics, and food centers. With nearly 20% of the workforce lost and hiring freezes persisting, employees report low trust in leadership and regulatory challenges. This attrition jeopardizes the agency’s regulatory functions during a critical time of scientific and public health demands. The impacts are detailed in multiple reports highlighting risks to drug and device review processes.